Dyno Therapeutics
Dyno Therapeutics is pioneering AI-powered gene therapy, using machine learning and high-throughput experimentation to optimize AAV capsids for improved gene delivery.
Dyno Therapeutics Services
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. The company leverages machine learning and quantitative high-throughput in vivo experimentation to design gene vectors. Dyno Therapeutics uses its proprietary CapsidMap™ platform to systematically and rapidly optimize adeno-associated virus (AAV) capsids for improved gene delivery. This platform focuses on enhancing targeting ability, payload size, immune evasion, and manufacturability of AAV capsids.
Dyno Therapeutics Products
Dyno Therapeutics' primary product is the CapsidMap™ platform. This AI-driven system is used to design millions of capsid sequences, which are then synthesized on DNA printers and assembled into comprehensive capsid libraries. The CapsidMap™ platform leverages next-generation sequencing to track unique DNA barcodes, allowing the company to map the AAV capsid fitness landscape and iteratively improve gene therapy vectors through cycles of experimentation and optimization.
Dyno Therapeutics Collaborations
Dyno Therapeutics has established partnerships with several leading gene therapy companies, including Novartis, Sarepta, Roche, and Astellas. Notably, the collaboration with Roche and Spark Therapeutics focuses on developing next-generation AAV gene therapy vectors for central nervous system (CNS) diseases and liver-directed therapies, with potential milestone payments exceeding $1.8 billion. The partnership with Astellas aims at developing gene therapy vectors for skeletal and cardiac muscle, entailing an upfront payment of $18 million, with milestone and royalty payments potentially exceeding $1.6 billion.
Dyno Therapeutics Recognition and Funding
Dyno Therapeutics has been acknowledged on the Forbes list of America’s Best Startup Employers in both 2022 and 2023. The company was also named Emerging Company of the Year by the New England Venture Capital Association in 2021. In terms of funding, Dyno Therapeutics received $100 million in Series A financing led by Andreessen Horowitz. These accolades and financial investments underscore the company's innovative contributions to the gene therapy sector and its potential for future growth.
Dyno Therapeutics Technology
Dyno Therapeutics utilizes advanced technological platforms, prominently featuring their CapsidMap™ system. This platform employs state-of-the-art DNA library synthesis and next-generation DNA sequencing to measure gene delivery properties in high throughput environments. AI is integral to the CapsidMap™ platform, predicting the functionality of new capsid sequences and creating a comprehensive map of the AAV capsid fitness landscape. This iterative process of design, experimentation, and optimization aims to produce superior gene therapy vectors for a wide range of applications.